Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
0
Authors
Ronan Desmond
Ronan Desmond•Danielle Townsley•Cynthia Dunbar
Published
December 18, 2013
Abstract
Key Points Eltrombopag promotes hematopoiesis in patients with severe aplastic anemia by stimulating stem and progenitor cells. Eltrombopag can be discontinued safely in robust responders with maintenance of hematopoiesis.
